| Pricing and reimbursement of biosimilars in Central and Eastern European countries P Kawalec, E Stawowczyk, T Tesar, J Skoupa, A Turcu-Stiolica, ... Frontiers in pharmacology 8, 288, 2017 | 78 | 2017 |
| Pharmaceutical regulation in Central and Eastern European countries: a current review P Kawalec, T Tesar, L Vostalova, P Draganic, M Manova, A Savova, ... Frontiers in pharmacology 8, 892, 2017 | 45 | 2017 |
| The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for … B Godman, M Haque, T Leong, E Allocati, S Kumar, S Islam, J Charan, ... Frontiers in public health 9, 671961, 2021 | 38 | 2021 |
| When health technology assessment is confidential and experts have no power: the case of Hungary M Csanádi, O Löblová, P Ozierański, A Harsányi, Z Kaló, M McKee, ... Health Economics, Policy and Law 14 (2), 162-181, 2019 | 31 | 2019 |
| Drug policy in Hungary A Inotai, M Csanádi, A Harsányi, B Németh Value in health regional issues 13, 16-22, 2017 | 19 | 2017 |
| Comparative analysis of legislative requirements about patients' access to biotechnological drugs for rare diseases in Central and Eastern European Countries M Kamusheva, M Manova, AT Savova, GI Petrova, K Mitov, A Harsányi, ... Frontiers in pharmacology 9, 795, 2018 | 18 | 2018 |
| Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary A Harsányi, M Csanádi, K Márky, ÁZ Vincziczki, Z Kaló, A Inotai Expert review of pharmacoeconomics & outcomes research 20 (6), 653-659, 2020 | 17 | 2020 |
| Policy objective of generic medicines from the investment perspective: the case of clopidogrel P Elek, A Harsányi, T Zelei, Z Kaló Health Policy 121 (5), 558-565, 2017 | 14 | 2017 |
| Utilisation Trend of Long‐Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications B Godman, M Wladysiuk, S McTaggart, A Kurdi, E Allocati, M Jakovljevic, ... BioMed research international 2021 (1), 9996193, 2021 | 10 | 2021 |
| Pricing and reimbursement of patent-protected medicines: challenges and lessons from South-Eastern Europe L Vončina, T Strbad, J Fürst, M Dimitrova, M Kamusheva, M Vila, ... Applied health economics and health policy 19, 915-927, 2021 | 6 | 2021 |
| Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues B Godman, B Tubic, E Allocati, M Wladysiuk, S McTaggart, A Kurdi, ... Journal of Applied Pharmaceutical Science 12 (3), 055-072, 2022 | 5 | 2022 |
| coreNASH: Multi‐stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment E Clearfield, V Miller, J Nadglowski, K Barradas, J Al Naber, AJ Sanyal, ... Hepatology communications 5 (5), 774-785, 2021 | 4 | 2021 |
| PBI24 UTILIZATION AND SWITCHING PATTERNS OF BIOLOGICAL MEDICINES IN THE INDICATIONS OF INFLIXIMAB BEFORE AND AFTER PATIENT EXPIRY A Harsanyi, M Csanádi, K Marky, ÁZ Vincziczki, Z Kalo, A Inotai Value in Health 22, S51, 2019 | 1 | 2019 |
| Biosimilar Infliximab Utilization After Patent Expiry: The Case of Colitis Ulcerosa and Rheumatoid Arthritis in Hungary A Harsányi, M Csanádi, K Márky, B Németh, ÁZ Vincziczki, Z Kaló, ... Value in Health 21, S95-S96, 2018 | 1 | 2018 |
| Investment aspects of generic drug policies in countries with severe resource constraints Z Kaló, A Harsanyi, I Vamossy Value in Health 17 (7), A500, 2014 | 1 | 2014 |
| Corrigendum to “Utilisation Trend of Long‐Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” B Godman, M Wladysiuk, S McTaggart, A Kurdi, E Allocati, M Jakovljevic, ... BioMed Research International 2023 (1), 9757348, 2023 | | 2023 |
| Biosimilars are essential for sustainable healthcare systems across Europe; however, key challenges remain as seen with biosimilars for long-acting insulin analogues B Godman, B Tubić, E Allocati, M Wladysiuk, S McTaggart, A Kurdi, ... Journal of Applied Pharmaceutical Science 12 (3), 55-72, 2022 | | 2022 |
| PNS45 Pricing and Reimbursement of Innovative Medicines: Challenges and Lessons from South-Eastern Europe A Bobinac, I Banovic, D Atanasijevic, A Harsanyi, K Hristova, I Mardare, ... Value in health 24, S180-S181, 2021 | | 2021 |
| Gyógyszerpolitikai döntések hatása a gyógyszerek hozzáférhetőségére a szabadalomvesztést követően A Harsányi | | 2021 |
| Research Article Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications E Allocati, M Jakovljevic, F Kalemeera, I Hoxha, A Nachtnebel, ... | | 2021 |
